The asset at play is fipaxalparant, a candidate designed to block the lysophosphatidic acid receptor 1 (LPAR1). Amgen tested ...

As the Horizon acquisition reaps its benefits, Amgen is now turning eyes to its obesity and diabetes portfolio.

A recent study in the field of neurobiology, presented in Science China Life Sciences, uncovers a pivotal role for the ...

TCGFB, a private biotech founded by healthcare VC The Column Group, is tapping California biotech Surrozen to discover ...

and lysophosphatidic acid (LPA). These lipids activate crucial cellular pathways, including the mTOR pathway, which is ...

Biochem J. 2007 Oct 15;407(2):243-54. PubMed PMID: 17617061. Khurana S, Tomar A, George SP, Wang Y, Siddiqui MR, Guo H, Tigyi G, Mathew S. Autotaxin and lysophosphatidic acid stimulate intestinal cell ...

Dr. Iweka discovered that PLPPR1 impedes the inhibitory activity of CSPGs and other inhibitory molecules such as lysophosphatidic acid, by modulating Rho-GTPases during CNS injury. During her ...

Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive ...